This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages without signing in

BCG immunotherapy in bladder tumours

Authoring team

Intravesical BCG has been used to treat bladder cancer since the late 1970's. Given once a week for 6-12 weeks, it destroys carcinoma in situ and superficial tumours, and causes measurable changes in the immune system.

The main problem with intravesical BCG is it's side-effects:

  • systemic "BCG-osis" with lung granulomas, disturbed liver function, fever and malaise; requires prompt anti-tuberculous chemotherapy as may be fatal
  • chemical cystitis
  • flu-like symptoms

Consequently, BCG is usually reserved for:

  • carcinoma in situ
  • high grade superficial tumours i.e. pT1G3
  • pTa and pT1 tumours that have failed to respond to other treatments

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.